FDA Drug Topics: Project Facilitate: Oncology Expanded Access Program Update
December 14, 2020
FDA
This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety.
This webinar will discuss Expanded Access, the regulatory pathway by which an oncologist may obtain access to an investigational drug product for the purposes of treating a patient with a life-threatening medical condition for which there is no acceptable treatment. The FDA Oncology Center of Excellence's Project Facilitate was established to meet the demand for oncology Expanded Access through increasing awareness of this pathway, increasing accessibility and establishing a single point-of-contact for the public. Project Facilitate is continually improving oncology Expanded Access to ensure everyone has personalized support when submitting their application.
- Lemery, S., Mailankody, S., Kazandjian, D., Demiette Smit, M., Blumenthal, G., Kim, T., Keegan, P., McKee, A., Pazdur, R. (2016, June). Food and Drug Administration analysis of 1332 single patient and emergency use expanded access (compassionate use) requests for patients with cancer over a duration of three years (2012-2014). Abstract accepted and poster presented as American Society of Clinical Oncology Annual Meeting, Chicago, IL.
- Project facilitate: A review of the FDA oncology center of excellence expanded access pilot program. Natasha L Kormanik, Mitchell Chan, Jessica Boehmer, Tamy Kim, Gideon Michael Blumenthal, and Richard Pazdur. Journal of Clinical Oncology 2020 38:15_suppl, 7023-7023
- Reagan-Udall Foundation (n.d.). Expanded Access Navigator. Retrieved from https://reaganudall.org/
- Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling, policy and regulatory changes which would impact prescribing and medication management to optimize patient care.
- Define expanded access and the key requirements for an expanded access request for an individual patient.
- Summarize the key responsibilities of the oncology healthcare professional when considering expanded access for a patient.
- Identify resources available to healthcare professionals considering submission of an oncology expanded access request for an individual patient.
- Describe how Project Facilitate is a resource to navigate the oncology Expanded Access pathway.
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, CPH - Certified Public Health, and physician assistants.
Lecture 1 December 14, 2020
Time | Topic | Speaker |
---|---|---|
1:00 - 2:00 PM EST | Project Facilitate: Oncology Expanded Access Program Update | Mitchell Chan, PharmD, BCPS |
Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Faculty
- Chan, Mitchell, PharmD, BCPS, Clinical Analyst, FDA - nothing to disclose
Planning Committee
- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Cao, Christian, MPAS, PA-C, Cross-Discipline Safety Advisor, FDA/CDER/OSE/OPE - nothing to disclose
- De Fronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- Kapoor, Rama, MD, Senior Physician, FDA - nothing to disclose
- Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI - nothing to disclose
- Nguyen-Chu, Thanh, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
CE Consultation and Accreditation Team
- Lisa Thompson, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration is complimentary; therefore refunds are not applicable.